Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme present in every living cell. It serves as an essential cofactor in over 500 enzymatic reactions, playing critical roles in mitochondrial energy production, DNA repair, and cellular signalling pathways.
Studies in human tissue report lower NAD+ levels with age; Massudi et al. (2012, PLoS One) measured this in human skin samples across age groups. The size of the decline differs by tissue and measurement method, so no single percentage applies to everyone. In the research literature, lower NAD+ is associated with reduced mitochondrial function, impaired DNA repair capacity, and dysregulated circadian rhythms.
The decline in NAD+ is driven by multiple factors: increased activity of CD38 (an NAD+-consuming enzyme that increases with chronic inflammation), reduced activity of NAMPT (the rate-limiting enzyme in NAD+ biosynthesis), and accumulated DNA damage that activates PARP enzymes, which consume NAD+ during repair processes.
A large body of research examines whether raising NAD+ levels with precursors - primarily NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) - affects sirtuin activity, mitochondrial biogenesis and cellular ageing pathways in laboratory models.
Format matters for the research compound itself. NAD+ in solution is sensitive to pH, temperature and light, which is why the CELYFE Precision Pen supplies it pre-mixed, buffered and sealed in a cold-chain cartridge rather than as a powder reconstituted at the bench.
Current research continues to explore the relationship between NAD+ levels, sirtuin activation, and healthy ageing. While the field is promising, more long-term human clinical trials are needed to characterise it fully. Nothing here describes use in humans or animals; Celyfe pens are supplied for in-vitro laboratory research.
This article is an editorial piece and is provided for informational purposes only. It is not medical advice. Celyfe pens are supplied strictly for in-vitro laboratory research.